Skip to content

Study Details

Testing Inhaled Treprostinil in People with Idiopathic Pulmonary Fibrosis

(IRB#: IRB_00143600)

This study will test new a drug called Inhaled Treprostinil in people with Idiopathic Pulmonary Fibrosis (IPH). IPF is a disease that causes scarring in the lungs. The study wants to see if Inhaled Treprostinil will help people with IPF and is safe. People in this study will be randomly chosen to be treated with Inhaled Treprostinil or placebo. The placebo does not contain any medicine. Treprostinil and placebo are given by breathing the medicine into the lungs using a machine called a nebulizer (inhaling device). The nebulizer changes the medicine into a mist to breathe into the lungs. Being in this study requires about 8 clinic visits. Participation lasts about 58 weeks. Medical visits will be done during the study to track the health of participants.


  • All genders
  • Over 18 years old
  • Volunteers with special conditions
  •   In Person
  • Paid

Who can participate?

 Gender: All genders

  Age: Over 18 years old

  Volunteers: Volunteers with special conditions

   Location: In Person

Inclusion Criteria

  • Ages 40 years and older
  • Diagnosis of Idiopathic Pulmonary Fibrosis
  • Can be on Pirfenidone or Nintedanib (other drugs given for Idiopathic Pulmonary Fibrosis) started either 30 days or more before study participation
  • Able to attend in person at a study clinic

Exclusion Criteria

  • Pregnant or breastfeeding
  • Receiving a certain amount of extra oxygen for breathing
  • Severe IPF or active lung infection or other infections that affect breathing within 30 days prior to study participation
  • Uncontrolled cardiac (heart) disease

Will I be paid for my time?


For more information contact:

Cassie Larsen


IRB#: IRB_00143600

PI: Mary Beth Scholand

Department: PULMONARY

Approval Date: 2022-08-17 06:00:00

Specialties: Pulmonary

Last Updated: 6/8/23